V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220019655 | 220008435 | null | 83.2 | Disease modification (D) | 2017-04-05 | 2017-04-05 | BOSUTINIB | null | null | 220032025 | BOSUTINIB |
| 220019656 | 220008439 | null | 0 | Not known (9) | 2012-09-20 | 2015-06-23 | Methotrexate intrathecal | 02 | null | 220032028 | METHOTREXATE INTRATHECAL |
| 220019657 | 220008440 | 1.8 | 88.5 | Curative (C) | 2017-12-07 | 2017-12-07 | ATG + Busulfan + Fludarabine | N | N | 220032029 | ATG + BUSULFAN + FLUDARABINE |
| 220019658 | 220008442 | 1.6 | 75 | null | 2016-11-27 | 2016-12-24 | RUXOLITINIB | null | N | 220032039 | RUXOLITINIB |
| 220019659 | 220014577 | 1.62 | 74 | Palliative (P) | 2016-06-30 | 2016-06-30 | Triple / Double Intrathecal Therapy | N | N | 220032050 | TRIPLE INTRATHECAL |
| 220019660 | 220008448 | 1.67 | 87.8 | Curative (C) | 2017-08-27 | 2017-08-27 | RUXOLITINIB | N | N | 220032050 | RUXOLITINIB |
| 220019661 | 220008452 | 1.59 | 75 | Palliative (P) | 2013-01-15 | 2013-04-13 | IDARUBICIN + TRETINOIN | N | N | 220032058 | IDARUBICIN + TRETINOIN |
| 220019663 | 220008456 | 1.67 | 83.1 | Curative (C) | 2017-10-01 | 2017-10-24 | Triple / Double Intrathecal Therapy | 2 | N | 220032064 | TRIPLE INTRATHECAL |
| 220019664 | 220008458 | null | null | Curative (C) | 2015-02-03 | 2015-02-12 | AML16 DA 3+10 | N | null | 220032067 | AML16 TRIAL |
| 220019665 | 220008459 | 1.63 | 69 | Curative (C) | 2017-09-27 | 2017-11-28 | Cyclophosphamide TBI Allograft | null | null | 220032072 | CYCLOPHOSPHAMIDE |
| 220019666 | 220019867 | 1.59 | 52.5 | Palliative (P) | 2015-12-02 | 2015-12-09 | FLAG | 2 | N | 220032085 | FLAG |
| 220019667 | 220008463 | 1.78 | 81 | Curative (C) | 2016-03-17 | 2016-03-17 | Methotrexate intrathecal | 01 | null | 220032087 | METHOTREXATE INTRATHECAL |
| 220019668 | 220017975 | 1.82 | 88.8 | Curative (C) | 2016-03-31 | 2016-04-02 | Triple / Double Intrathecal Therapy | null | N | 220032105 | TRIPLE INTRATHECAL |
| 220019669 | 220008471 | 1.67 | null | Curative (C) | 2013-10-09 | 2013-10-12 | AML Int Guide ADE 8+3+5 (2) | N | N | 220032108 | ADE |
| 220019670 | 220008480 | null | 155 | Disease modification (D) | 2014-02-03 | 2014-02-03 | Triple / Double Intrathecal Therapy | N | N | 220032113 | TRIPLE INTRATHECAL |
| 220019671 | 220008481 | 1.63 | 155 | Disease modification (D) | 2017-11-12 | 2017-11-13 | Cyclophosphamide TBI Allograft | Y | N | 220032113 | CYCLOPHOSPHAMIDE |
| 220019672 | 220008483 | 1.68 | 17.05 | Curative (C) | 2014-10-01 | 2014-10-04 | Methotrexate intrathecal | N | N | 220032121 | METHOTREXATE INTRATHECAL |
| 220019673 | 220017981 | 1.66 | 57.3 | Curative (C) | 2014-11-15 | 2014-11-18 | BOSUTINIB | 02 | null | 220032126 | BOSUTINIB |
| 220019674 | 220014595 | null | 94.6 | Disease modification (D) | 2018-03-25 | 2018-03-30 | Cyclophosphamide+Fludara+TBI Allo | 99 | null | 220032142 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220019675 | 220008493 | 1.62 | null | Palliative (P) | 2014-06-13 | 2014-06-14 | AML16 Low Dose Cytarabine | N | N | 220032156 | AML16 TRIAL |
| 220019676 | 220014600 | 1.83 | 87.8 | Disease modification (D) | 2014-08-19 | 2015-01-14 | BOSUTINIB | null | N | 220032158 | BOSUTINIB |
| 220019677 | 220008504 | 1.67 | 80 | null | 2013-10-08 | 2013-10-14 | ATG + Busulfan + Fludarabine | null | null | 220032159 | ATG + BUSULFAN + FLUDARABINE |
| 220019678 | 220017985 | 1.75 | null | Curative (C) | 2015-12-21 | 2016-01-04 | RUXOLITINIB | N | N | 220032164 | RUXOLITINIB |
| 220019680 | 220021567 | 1.84 | 25.3 | Palliative (P) | 2014-05-30 | 2014-09-21 | PONATINIB | 2 | N | 220032173 | ECX |
| 220019681 | 220008517 | 1.71 | 81.2 | Curative (C) | 2016-01-30 | 2016-02-04 | Oxaliplatin + Modified de Gramont | N | N | 220032200 | CLOFARABINE + CYTARABINE |
| 220019682 | 220008519 | null | 13.6 | Adjuvant (A) | 2019-03-01 | 2019-03-15 | UKALL 14 TRIAL | N | N | 220032218 | FLUDARABINE + MELPHALAN |
| 220019683 | 220014611 | 1.42 | 58 | Curative (C) | 2015-06-28 | 2015-11-06 | Paclitaxel 80mg/m2 day 1 8 15 | N | N | 220032225 | PACLITAXEL |
| 220019684 | 220008523 | 1.73 | null | Palliative (P) | 2014-07-20 | 2015-03-15 | IDARUBICIN | N | N | 220032227 | IDARUBICIN |
| 220019685 | 220008526 | 1.67 | 66 | Curative (C) | 2016-02-29 | 2016-03-05 | Mitox + Tretinoin Spanish Course 3 | 2 | N | 220032236 | MITOXANTRONE |
| 220019686 | 220008527 | 1.9 | 86.5 | Not known (9) | 2016-02-26 | 2016-04-19 | Fludarabine + Melphalan RIC Allo | null | null | 220032251 | DOCETAXEL |
| 220019687 | 220008531 | 1.6 | 75 | Curative (C) | 2014-07-14 | 2014-07-15 | Clofarabine + Cytarabine | Y | N | 220032254 | UKALL2014 |
| 220019689 | 220008539 | 1.86 | 84.4 | Curative (C) | 2013-08-17 | 2013-08-17 | GemCarbo Days 1+8 | 2 | null | 220032265 | METHOTREXATE |
| 220019690 | 220014619 | 1.6 | 76.45 | Curative (C) | 2016-08-23 | 2016-08-23 | UKALL14- Ph 2 Induction | 2 | N | 220032271 | GEMCARBO |
| 220019691 | 220008543 | null | 83.6 | Disease modification (D) | 2013-07-13 | 2014-01-01 | CARBOPLATIN + PACLITAXEL | 02 | N | 220032272 | CARBOPLATIN + PACLITAXEL |
| 220019692 | 220008554 | 1.6 | 46.6 | Curative (C) | 2017-11-21 | 2018-02-27 | CISPLATIN + GEMCITABINE | 02 | N | 220032313 | ECX |
| 220019693 | 220008557 | 1.89 | 105 | Disease modification (D) | 2019-02-17 | 2019-03-03 | Carboplatin + Paclitaxel (3 weekly) | N | N | 220032316 | CARBOPLATIN + PACLITAXEL |
| 220019694 | 220008558 | 1.78 | null | Curative (C) | 2017-01-08 | 2017-01-10 | Fludarabine + Melphalan RIC Allo | 2 | N | 220032319 | PONATINIB |
| 220019695 | 220008561 | null | 61 | Curative (C) | 2013-09-06 | 2015-01-10 | FLUDARABINE + MELPHALAN | N | N | 220032328 | IRINOTECAN + MDG |
| 220019696 | 220014626 | null | 48.7 | Curative (C) | 2015-10-22 | 2015-10-23 | Carboplatin + Paclitaxel (3 weekly) | N | N | 220032331 | CARBOPLATIN + PACLITAXEL |
| 220019697 | 220008570 | null | 81.7 | Curative (C) | 2014-04-19 | 2014-05-09 | Carboplatin + Etoposide iv&po | Y | N | 220032351 | CARBOPLATIN + ETOPOSIDE |
| 220019698 | 220017998 | 1.68 | 100.8 | Curative (C) | 2013-12-26 | 2013-12-26 | Mitox + Tretinoin Spanish Course 3 | 2 | N | 220032371 | MITOXANTRONE |
| 220019699 | 220008579 | 1.73 | 60 | Curative (C) | null | 2017-08-31 | IDARUBICIN | null | null | 220032378 | IDARUBICIN |
| 220019700 | 220014634 | 1.55 | null | Curative (C) | 2017-07-23 | 2017-10-09 | METHOTREXATE | N | null | 220032382 | PONATINIB |
| 220019701 | 220014636 | 1.84 | 60 | null | 2016-10-05 | 2016-10-12 | GEMTUZUMAB OZOGAMICIN | 01 | N | 220032405 | CISPLATIN + GEMCITABINE |
| 220019702 | 220008590 | 1.64 | 77.8 | Curative (C) | 2012-08-18 | 2014-03-23 | Carboplatin + Paclitaxel (3 weekly) | N | N | 220032418 | CARBOPLATIN + PACLITAXEL |
| 220019703 | 220008599 | 1.63 | 70 | Curative (C) | 2016-09-09 | 2016-09-09 | Docetaxel 75mg/m2 (21 day) | N | N | 220032464 | PONATINIB |
| 220019704 | 220008604 | 1.71 | 72 | Curative (C) | 2017-07-06 | 2017-07-15 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | Y | N | 220032476 | CISPLATIN + GEMCITABINE |
| 220019705 | 220008604 | 1.63 | 68.199 | Curative (C) | 2014-02-02 | 2014-07-12 | CARBOPLATIN + ETOPOSIDE | N | null | 220032476 | CARBOPLATIN + ETOPOSIDE |
| 220019706 | 220014650 | null | 60 | Palliative (P) | 2015-09-15 | 2015-09-18 | Carboplatin + Etoposide iv&po | 02 | N | 220032524 | CARBOPLATIN + ETOPOSIDE |
| 220019707 | 220008621 | 1.77 | 84.45 | Adjuvant (A) | 2016-02-20 | 2016-04-08 | Arsenic Triox + Tretinoin Ind W5-8 | N | N | 220032532 | ARSENIC TRIOXIDE + TRETINOIN |